Christi Shaw (Kite)
April 4, 2022 12:58 PM EDTUpdated April 8, 03:03 AM
Pharma
Cell/Gene Tx
Marketing

Gilead­'s land­mark CAR-T ap­proval leaves Bris­tol My­ers Squibb scram­bling for sec­ond place

Nicole DeFeudis

Editor

You’ve got to be quick­er than that, Bris­tol My­ers Squibb. Gilead’s Kite scored a land­mark ap­proval for Yescar­ta in large B-cell lym­phoma (LB­CL) on Fri­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times